Close Menu

Immunoassays

News on immunoassay systems and applications.

Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.

BillionToOne's test is based on the company's proprietary Sanger sequencing approach, while Sugentech's test detects antibodies against SARS-CoV-2.

Some of the firms will receive money to speed up test development, while others will use the funds to expand their testing and manufacturing capacity.

QDx's RT-PCR-based test is designed to detect the SARS-CoV-2 N gene, while Biocan's immunoassay is designed to detect antibodies against the virus.

IsoPlexis' single-cell proteomics products will be made available to researchers in these countries through Medquest.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.